Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. As a pioneer in biotechnology since 1980, Amgen uses living cells to make biologic medicines addressing cardiovascular metabolic conditions, oncology, inflammation, rare diseases, and bone health, operating in approximately 100 countries worldwide.
More than an index entry, but the surface is still mostly links rather than artifacts — the cohort most likely to move a full band from modest, well-targeted work.
API Evangelist profiles Amgen the way a machine reads it — 19 machine-readable artifacts across 1 API, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Amgen scores 26.4/100 (emerging), with a separate agent-readiness read of 7/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Amgen
Each block below is one kind of artifact we hold for Amgen. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
APIs 1
Each API is captured as its own OpenAPI definition — every operation, parameter, and response. This is the single most useful machine-readable description of what an API does, and it's what lets us score, lint, mock, and generate against it without asking the provider for anything.
Individual APIs this provider publishes, each with its own machine-readable definition.
Amgen Website
Amgen discovers, develops, manufactures, and delivers innovative biologic medicines for patients with serious illnesses. The company does not currently publish a public develope...
Pricing Plans 1
Pricing is part of the interface. Machine-readable plans tell you what a tier costs and includes before you commit — one of the six things the Kin Score reads for commercial clarity.
Published pricing tiers and plan structures.
Amgen Plans Pricing
PLANSRate Limits 1
Rate limits are the difference between a demo that works and a production integration that doesn't fall over. Publishing them is an operational-transparency signal — and a hard requirement for any agent that plans its own throughput.
Documented rate limits and quota policies.
Amgen Rate Limits
RATE LIMITSFinOps 1
Cost, billing, and metering signals let a buyer model the financial operations of an API before it's live. We profile them for the same reason we profile pricing: the money is part of the contract.
Cost, billing, and metering signals for API financial operations.
Amgen Finops
FINOPSFeatures 8
The notable capabilities this provider advertises, captured as structured features so they can be searched and compared instead of read one landing page at a time.
Notable capabilities this provider offers.
Biologic Drug Discovery
Pioneering use of living cells and human genetic data combined with AI and generative biology to discover novel biologic medicines.
Oncology Therapeutics
Cancer medicines targeting solid tumors and hematologic malignancies including innovative BiTE and antibody therapies.
Cardiovascular and Metabolic Medicines
Medicines addressing heart disease, high cholesterol (Lp(a)), obesity, and obesity-related metabolic conditions.
Inflammation Therapeutics
Treatments for inflammatory conditions including chronic rhinosinusitis with nasal polyps, asthma, and other immune-mediated diseases.
Rare Disease Medicines
Therapies for rare conditions including IgG4-related disease (IgG4-RD), generalized myasthenia gravis, and other orphan indications.
Bone Health Products
Medicines for osteoporosis, bone metastases, and other bone health conditions including PROLIA and XGEVA.
Biosimilars
High-quality biosimilar medicines providing more affordable alternatives to reference biologic therapies across multiple therapeutic areas.
AI-Driven Drug Development
Application of artificial intelligence, generative biology, and advanced data science to accelerate drug discovery and clinical trial optimization.
Scroll within the panel for all 8 ·
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Use Cases 6
What developers actually build with this provider — captured so the catalogue answers 'what is this for', not just 'what does this expose'.
What developers build with this provider.
Cancer Treatment
Providing oncology medicines for patients with solid tumors and blood cancers through innovative biologic and targeted therapies.
Heart Disease Prevention
Reducing cardiovascular risk with medicines targeting LDL cholesterol, Lp(a), and other cardiovascular risk factors.
Inflammatory Disease Management
Managing chronic inflammatory conditions with targeted biologic therapies for patients with severe unmet medical needs.
Rare Disease Treatment
Delivering life-changing therapies to patients with rare and ultra-rare diseases where few or no other treatments exist.
Biosimilar Access
Improving patient access to biologic therapies through high-quality, lower-cost biosimilar medicines.
Weight Management
Addressing obesity and obesity-related conditions with novel medicines targeting metabolic pathways.
Resources
Every other property we hold for Amgen — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Get Started 1
Portal, sign-up, and the first successful call
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Learn 1
Tutorials, courses, talks, and written guidance
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Other 1
Properties that don't map to a standard resource type
← All providers · Data indexed from github.com/api-evangelist/amgen · machine-readable index on apis.io